Prestige Consumer Healthcare Inc. PBH R2K
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Profit CAGR of 110.4% over 5 years.
- Generates positive free cash flow.
CONS
- Revenue declined at -1.2% CAGR over 5 years.
- Trading 45.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PBH Prestige Consumer Healthcare Inc. R2K | 47.53 | 12.16 | $2.25B | - | 8.89% | 10.22% | -1.17% | 110.40% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 256.57M | 258.03M | 270.62M | 255.97M | 253.98M | 239.36M | 241.41M | 241.03M | 232.15M | 238.07M | 241.55M | 251.24M | 229.39M | 237.42M | 238.79M | 269.18M | 276.23M | 274.47M | 277.06M | 289.27M | 275.52M | 279.31M | 286.32M | 282.74M | 267.14M | 283.79M | - | 296.52M | 249.53M | 274.11M | 283.44M | 281.62M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 126.51M | 109.20M | 122.53M | 126.08M | 135.32M |
| Gross Profit | 112.24M | 119.94M | 116.78M | 118.25M | 121.59M | 123.97M | 124.55M | 130.18M | 143.48M | 144.10M | 147.67M | 141.26M | 140.62M | 137.47M | 139.24M | 138.25M | 134.07M | 136.75M | 137.50M | 143.91M | 133.87M | 137.66M | 138.89M | 159.01M | 157.71M | 155.06M | 160.12M | 161.01M | 150.40M | 154.67M | 160.02M | 157.94M | 146.02M | 157.38M | - | 170.01M | 140.33M | 151.58M | 157.37M | 146.30M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 69.12M | 68.58M | 71.91M | 74.88M | 70.81M |
| Operating Income | 62.51M | 69.90M | 62.64M | 65.27M | 12.21M | 71.06M | 69.29M | 53.05M | 78.95M | 75.72M | 83.89M | -23.10M | 72.49M | 70.92M | 77.54M | -153.45M | 71.49M | 69.35M | 76.40M | 73.92M | 80.12M | 72.90M | 73.44M | 91.34M | 78.56M | 82.59M | 87.01M | 84.38M | 87.18M | 85.19M | 88.25M | 86.83M | 72.05M | 84.34M | - | 100.89M | 71.76M | 79.67M | 82.49M | 75.49M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 91.97M | 79.65M | 86.83M | 80.08M | 84.55M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.76M | 10.20M | 10.04M | 10.67M | 11.43M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 73.96M | 61.78M | 69.13M | 61.81M | 64.77M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.83M | 14.31M | 26.92M | 15.12M | 10.84M |
| Net Income | 26.17M | 31.80M | 28.00M | 13.94M | -5.53M | 32.20M | 31.64M | 11.09M | 33.76M | 30.70M | 314.79M | -39.69M | 34.47M | 30.84M | 38.17M | -139.27M | 33.92M | 33.25M | 38.06M | 37.05M | 43.71M | 44.59M | 40.87M | 57.76M | 45.33M | 50.22M | 55.27M | 51.02M | 51.95M | 53.28M | 53.56M | 53.05M | 49.07M | 54.38M | - | 50.13M | 47.47M | 42.21M | 46.70M | 53.93M |
| Diluted EPS | 0.49 | 0.60 | 0.53 | 0.26 | -0.10 | 0.60 | 0.59 | 0.21 | 0.63 | 0.57 | 5.88 | -0.75 | 0.65 | 0.59 | 0.73 | -2.68 | 0.65 | 0.65 | 0.75 | 0.73 | 0.86 | 0.88 | 0.81 | 1.14 | 0.89 | 0.99 | 1.09 | 1.02 | 1.04 | 1.06 | 1.07 | 1.06 | 0.98 | 1.09 | 1.22 | 1.00 | 0.95 | 0.86 | 0.97 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 882.06M | 1.04B | 975.78M | 963.01M | 943.37M | - | 1.13B | 1.13B | 1.14B | 1.09B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 502.43M | 500.91M | 503.30M | 493.13M |
| Gross Profit | 153.44M | 170.88M | 227.38M | 343.74M | 335.55M | 406.22M | 467.21M | 500.29M | 576.50M | 555.58M | 552.22M | 547.47M | - | 625.29M | 624.45M | 634.46M | 595.58M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 277.49M | 282.02M | 285.22M | 286.17M |
| Operating Income | 78.33M | 76.14M | 102.82M | 191.88M | 188.62M | 207.56M | 260.31M | 205.64M | 215.47M | 67.50M | 291.15M | 297.40M | - | 347.80M | 342.43M | 349.24M | 309.41M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.87M | 373.86M | 361.99M | 331.11M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 69.16M | 67.16M | 47.63M | 42.34M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -93.92M | 276.02M | 284.19M | 257.50M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.61M | 66.69M | 69.58M | 67.19M |
| Net Income | 32.12M | 29.22M | 37.21M | 65.50M | 72.61M | 78.26M | 99.91M | 69.39M | 339.57M | -35.80M | 142.28M | 164.68M | - | -82.31M | 209.34M | 214.60M | 190.30M |
| Diluted EPS | 0.64 | 0.58 | 0.73 | 1.27 | 1.39 | 1.49 | 1.88 | 1.30 | 6.34 | -0.69 | 2.78 | 3.25 | 4.04 | -1.65 | 4.17 | 4.29 | - |
Compounded Sales Growth
| 5 Years: | -1.17% |
| 1 Year: | -5.00% |
Compounded Profit Growth
| 5 Years: | 110.40% |
| 1 Year: | 12.40% |
Stock Price Performance
| 1 Year: | -44.52% |
| 6 Months: | -19.45% |
| 3 Months: | -31.41% |
| 1 Month: | -15.16% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.06B | 1.76B | 1.74B | 1.80B | 2.64B | 2.95B | 3.91B | 3.76B | 3.44B | 3.51B | 3.43B | - | 3.35B | 3.32B | 3.40B | 3.49B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 391.74M | 375.04M | 448.33M | 431.48M |
| Cash & Equivalents | 35.18M | 41.10M | 13.33M | 19.02M | 15.67M | 28.33M | 21.32M | 27.23M | 41.85M | 32.55M | 27.53M | 94.76M | 32.30M | - | 58.49M | 46.47M | 97.88M | 63.87M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 162.12M | 138.72M | 147.71M | 159.13M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 183.37M | 185.03M | 202.04M | 208.57M |
| Total Liabilities | - | - | 695.09M | 1.36B | 1.26B | 1.23B | 2.01B | 2.20B | 3.09B | 2.58B | 2.35B | 2.34B | 2.07B | - | 1.91B | 1.66B | 1.57B | 1.61B |
| Current Liabilities | - | - | 54.21M | 63.92M | 96.67M | 84.36M | 99.04M | 106.68M | 162.01M | 123.20M | 126.98M | 149.88M | 122.14M | - | 160.72M | 117.05M | 106.62M | 120.92M |
| Long Term Debt | - | - | 486.94M | 1.12B | 970.90M | 934.41M | 1.56B | 1.63B | 2.19B | 1.99B | 1.80B | 1.73B | 1.48B | - | 1.35B | 1.13B | 992.36M | 993.95M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.37B | 1.14B | 1.04B | 1.05B |
| Total Equity | 294.38M | 329.06M | 361.83M | 402.73M | 477.94M | 563.36M | 627.62M | 744.34M | 822.55M | 1.18B | 1.10B | 1.17B | 1.36B | - | 1.45B | 1.66B | 1.83B | 1.89B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.86M | 55.50M | 56.01M | 56.21M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 59.43M | 86.67M | 67.45M | 137.60M | 111.58M | 156.25M | 176.31M | 148.67M | 210.11M | 189.28M | 217.12M | 235.61M | - | 229.72M | 248.93M | 251.51M | 257.63M |
| Investing Cash Flow | 7.32M | -275.68M | -662.21M | 11.22M | -57.98M | -805.26M | -222.97M | -694.60M | -11.56M | 55.43M | -16.57M | -22.24M | - | -11.58M | -20.11M | -17.45M | -136.84M |
| Financing Cash Flow | -60.83M | 161.25M | 600.43M | -152.12M | -41.15M | 643.26M | 52.08M | 560.96M | -208.96M | -249.33M | -131.43M | -279.42M | - | -185.85M | -241.01M | -182.07M | -156.06M |
| Capital Expenditure | -673.00K | -655.00K | -606.00K | -10.27M | -2.76M | -6.10M | -3.57M | -2.98M | -12.53M | -10.48M | -14.56M | -22.24M | - | -7.78M | -9.55M | -8.22M | -11.18M |
| Free Cash Flow | 58.75M | 86.02M | 66.85M | 127.34M | 108.82M | 150.15M | 172.74M | 145.69M | 197.58M | 178.80M | 202.56M | 213.36M | - | 221.93M | 239.38M | 243.29M | 246.45M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.29M | -12.20M | 51.99M | -35.28M |
| Share Buybacks | - | - | - | - | - | - | - | 0 | 0 | 49.98M | 56.72M | 11.87M | 0 | 50.00M | 25.00M | 51.51M | 156.28M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | 56.7% | 55.4% | 56.9% | 57.3% | 58.0% | - | 55.4% | 55.5% | 55.8% | 54.7% |
| Operating Margin % | - | - | - | - | - | - | - | 23.3% | 20.7% | 6.9% | 30.2% | 31.5% | - | 30.8% | 30.4% | 30.7% | 28.4% |
| Net Margin % | - | - | - | - | - | - | - | 7.9% | 32.6% | -3.7% | 14.8% | 17.5% | - | -7.3% | 18.6% | 18.9% | 17.5% |
| ROE % | 9.8% | 8.1% | 9.2% | 13.7% | 12.9% | 12.5% | 13.4% | 8.4% | 28.8% | -3.3% | 12.2% | 12.1% | - | -5.7% | 12.6% | 11.7% | 10.1% |
| ROCE % | - | 7.6% | 6.1% | 11.7% | 11.0% | 8.2% | 9.2% | 5.5% | 5.9% | 2.0% | 8.7% | 9.0% | - | 10.9% | 10.7% | 10.6% | 9.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.60% | 7.39M | $351.17M |
| 2 | Ariel Investments, LLC | 9.02% | 4.27M | $203.16M |
| 3 | Vanguard Portfolio Management LLC | 5.92% | 2.80M | $133.27M |
| 4 | Dimensional Fund Advisors LP | 5.64% | 2.67M | $127.04M |
| 5 | Kayne Anderson Rudnick Investment Management LLC | 4.65% | 2.20M | $104.69M |
| 6 | Vanguard Capital Management LLC | 4.42% | 2.09M | $99.48M |
| 7 | State Street Corporation | 4.16% | 1.97M | $93.68M |
| 8 | Allspring Global Investments Holdings, LLC | 3.29% | 1.56M | $74.06M |
| 9 | Geode Capital Management, LLC | 3.08% | 1.46M | $69.40M |
| 10 | Morgan Stanley | 2.87% | 1.36M | $64.52M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PBH